Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note released on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Titan Pharmaceuticals stock opened at $3.64 on Friday. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The business has a fifty day moving average of $3.76 and a two-hundred day moving average of $3.82. The company has a market cap of $3.32 million, a P/E ratio of -0.70 and a beta of 1.27.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings data on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.